Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
November 21, 2017

TEL AVIV, Israel , Nov. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate overview via a Fireside Chat...

November 17, 2017

TEL AVIV, Israel , Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the pricing of its previously announced underwritten...

November 16, 2017

TEL AVIV, Israel , Nov. 16, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it is offering to sell 2,500,000 ordinary shares in...

November 14, 2017

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced...

November 09, 2017

TEL AVIV, Israel , Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Andrew Brenner , MD, will present a poster on VB-111...

November 07, 2017

TEL AVIV, Israel , Nov. 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

November 06, 2017

 Agreement includes $15 million up front, potential milestones payments of more than $100 million, as well as tiered high-teen royalties NanoCarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world TEL AVIV, Israel, Nov....

October 23, 2017

TEL AVIV, Israel , Oct. 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today the opening of its new gene therapy manufacturing plant in Modiin, Israel . This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec...

October 20, 2017

New EMA orphan approval for Ovarian Cancer complements previously granted VB-111 orphan status for Glioblastoma in the US and Europe TEL AVIV, Israel , Oct. 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and...

October 02, 2017

Top-line data expected in Q1 2018 TEL AVIV, Israel , Oct. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the independent Data Safety Monitoring Committee (DSMC) met on September 28, 2017 to conduct its third and final safety review of the Phase 3 GLOBE Study...

View all press releases »